IN THE UN D STATES PATENT AND TRADEMA

JCO6 Rec'd PCT/PTO

Group Art Unit: Not yet assigned

plicant:

Hagit ELDAR-FINKELMAN

Serial No.:

10/538,171

Filed:

June 9, 2005

For:

GLYCOGEN SYNTHASE KINASE-3 INHIBITORS

Docket: 29724

Attorney

· Examiner:

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Sir:

Enclosed is a PTO Form 1449 which lists citations which may be material to the patentability and examination of the above identified application. Also enclosed are copies of the references cited. These are submitted in compliance with the duty of disclosure defined in 37 CFR 1.56. The Examiner is requested to make these citations of official record in this application.

This Information Disclosure Statement under 37 CFR 1.56 is not to be construed as a representation that a search has been made, that additional matter which is material to the examination of this application does not exist, or that any or more of these citations constitutes prior art.

Respectfully submitted,

Martin O. Maynihan

Martin Moynihan

Registration No. 40,338

Dated: August 24, 2005



PTO/SB/08a (08-03)

Approved for use through 07/31/2006. OMB 0651-0031 U.S.Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

k Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Complete if Known Substitute for form 1449A/PTO Application Number 10/538,171 INFORMATION DISCLOSURE Filing Date June 9, 2005 STATEMENT BY APPLICANT First Named Inventor **ELDAR-FINKELMAN Hagit** Art Unit (use as many sheets as necessary) Not yet assigned Examiner Name Sheet of Attorney Docket Number 29724 U.S. PATENT DOCUMENTS Examiner Cite Document Number Publication Date Name of Patentee or Pages, Columns, Lines, Where MM-DD-YYYY Initials* Nο Applicant of Cited Document Relevant Passages or Relevant Figures Appear Number-Kind Code² (if known) US-6,153,618 11-28-2000 Schultz et al. 2 US-6,057,117 02-2-2000 Harrison et al. 3 US-1,471,621 10-23-1923 McCord US-2,046,068 06-30-1936 4 Gray 5 US-3,193,159 06-6-1965 Swindler 6 US-4,186,646 05-5-1980 Martin 7 US-5,462,101 10-31-1995 Mouchmouchian

		FOREIGN	PATENT DOC	UMENTS			
Examiner Initials*	Cite No. 1	Foreign Patent Documents Country Code ³ · Number ⁴ · Kind Code ⁵ (if known)	Publication Date MM-DD-YYYY		of Patentee or of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T
	8	PCT WO 95/01376	01-12-1995	Comoglio	et al.		
	9	PCT WO 01/49709	07-12-2001	Eldar-Fin	kleman		
	10	PCT WO 02/24941	03-28-2002	Biondi et	al.		П
	11	PCT WO 00/59206	05-5-2000	Mendlovi	c et al.		П
	12	PCT WO 00/45237	03-3-2000	Cohen-Or	et al.		
	13	PCT WO 00/74663	12-14-2000	Rosenthal	et al.		
	14	PCT WO 98/16528	04-23-1998	Schultz et	al.		П
	15	PCT WO 2005/000192	06-6-2005	Eldar-Fin	kleman		П
	16	PCT WO 97/33601	09-18-1997	Shaw et a	1.		П
	17	PCT WO 97/41854	11-13-1997	Klein et a	1.		П
							П
Examine Signatur					Date Considered		

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Translation is attached.
This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. this collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS.

SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450



PTO/SB/08b (08-03)
Approved for use through 06/30/2006. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE formation unless it contains a valid OMB control number.

		Act of 1995, no persons are required to respond to a collection of information un ostitute for form 1449A/PTO	Complete i	f Known		
			Application Number	10/538,		
	INF	ORMATION DISCLOSURE			ne 9, 2005	
	STA	TEMENT BY APPLICANT	First Named Inventor	ELDAR	 LMAN Hagit	
			Group Art Unit		assigned	
		(use as many sheets as necessary)	Examiner Name	1.01) 01	abbigited.	
Sheet		Of	Attorney Docket Number	29724		
		OTHER PRIOR ART – NON PATENT LITERA	ATURE DOCUMENTS			
Examiner	Cite	Include name of the author (in CAPITAL LETTERS), title of the a				
Initials	No.1	item (book, magazine, journal, serial symposium, catalog, etc.) dal publisher, city and/or country where pu		er(s),	T ²	
	18	Donella-Deana et al. "Dephosphorylation of Phosphope				
	1.0	(Protein Phosphatase 2B)", Eur. J. Biochem., 219(1-2):				
	19	Otaka et al. "Synthesis and Application of N-Box-L-2-				
	1.	4-,4-Difluorobutanoic Acid for Solid-Phase Synthesis				
		Phosphoserine Peptide Analogues", Tetrahedron. Lett.,				
	20	Othaka et al. "Development of New Methodology for the		alized	-	
		α-Fluorophosphonates and Its Practical Application to				
		Phosphopeptide Mimetics", Chem. Commun., 12: 1081				
	21	Pap et al. "Role of Glycogen Synthase Kinase-3 in the			•	
		Kinase/Akt Cell Survival Pathway", J. Biol. Chem., 27		l		
	22	Phiel "Molecular Targets of Lithium Action", Annu. Re	ev. Pharmacol. Toxicolog	gy,		
		41: 789-813, 2001.				
	23	Barrett et al. "Proteinase Inhibitors", Research Monogra	aphs in Cell and Tissue			
		Physiology, V-XXII,1986.				
	24	Roller et al. "Potent Inhibition of Protein-Tyrosine Pho				
		Phosphotyrosyl Mimetic Fluoro-O-Malonyl Tyrosine (FOMT)", Bioorg. Med. C	Chem.		
		Lett., 8(16): 2149-2150, 1998.				
	25	Rubinfeld et al. "Binding of GSK3Beta to the APC-Bet		İ		
	1	Regulation of Complex Assembly", Science, 272(5264				
	26	Sambrook et al. "Molecular Cloning: A Laboratory Ma	nual", Cold Spring Harbo	our		
 		Press, 2nd Ed., V-XXXII,1989.				
	27	Schiller et al. "Synthesis for Side-Chain Cyclized Pepti				
	28	Supports", Int. J. Peptide Protein Res., 25: 171-177, 19 Shapiro et al. "Combained Fmoc-Alloc Strategy for A				
	20	Phosphoserine Peptides: Preparation of Phosphorylatio				
		Bioorg. Med. Chem., 5(1): 147-156, 1997.	n-Dependent Tau Antisei	a,		
	29	Sherman et al. "Compatibility of Thioamides With Rev	verce Turn Features: Synt	hacic		
	27	and Conformational Analysis of Two Model Cyclic Pse		110313		
		Thioamides as Backbone Modifications", Journal of the		ciety		
		112: 433-441, 1990.		1.0.5,		
	30	Shulman et al. "Quantitation of Muscle Glycogen Synt	hesis in Normal Subjects	and		
		Subjects With Non-Insulin-Dependent Diabetes by 130				
		Spectroscopy", New England Journal of Medicine, 322		İ		
	31	Stambolic et al. "Lithium Inhibits Glycogen Synthase I		mics		
		Wingless Signalling in Intact Cells", Curr. Biol., 6: 166				
	32	ter Haar et al. "Structure of GSK-3 Beta Reveals A Prin				
		Mechanism", Nat. Struct. Biol., 8(7): 593-596, 2001.				
	33	Thomas "Excitatory Amino Acids in Health and Diseas	se", J. Am. Geriatr. Soc.,	43:		
		1279-1289, 1995.				
	34	Thorsett et al. "Dipeptide Mimics. Conformationally R				
		Angiotensin-Converting Enzyme", Biochem. Biophys.	Res. Commun., 111(1):	166-		
	<u> </u>	171, 1983.				
	35	Tong et al. "Activation of Glycogen Synthase Kinase-3				
		Platelet Activating Factor Mediates Migration and Cell	Death in Cerebellar Gra	nule		
		Neurons", Eur. J. Neurosci., 13: 1913-1922, 2001.				
	36	Veber et al. "Conformationally Restricted Bicyclic Ana	alogs of Somatostatin", P	roc.		
		Natl. Acad. Sci. USA, 75(6): 2636-2640, 1978.				

40gs	37	Welsh et Slycogen Synthase Kinase-3 Is Rapidly Inactivate esponse to	
4 1005 y		Insulin and Asphorylates Eukaryotic Initiation Factor Eif-2B", L. Chem. J., 294(Pt 3): 625-629, 1993.	
- 3	38	Wiemann et al. "Synthesis of Suitably Protected Hydroxymethylene Phosphonate-	
RADENIE	30	and 'Phosphat Phosphonate'-Analogues of Phosphoserine and Their Incorporation	
		Into Synthetic Peptides", Tetrahedron, 56: 1331-1337, 2000.	
	39	Ye et al. "L-O-(2-Malonyl)Tyrosine: A New Phosphotyrosyl Mimetic for the	
	37	Preparation of Src Homology 2 Domain Inhibitory Peptides", J. Med. Chem., 38(21):	
		4270-4275, 1995.	
	40	Eldar-Finkleman et al. "The Insulin Mimetic Action of Glycogen Synthase Kinase-3	
	'`	Inhibitors", Diabetologia, 45(Suppl.2): A 70, 38th Annual Meeting for the European	
		Association for the Study of Diabetes (EASD), Budapest, Hungary, 2002. Abstract.	
-	41	Plotkin et al. "Insulin Mimetic Action of Synthetic Phosphorylated Peptide Inhibitors	
	' -	of Glycogen Synthase Kinase-3", Journal of Pharmacology and Experimental	
		Therapeutics, 305(3): 974-980, 2003.	
	42	Leclerc et al. "Indirubins Inhibit Glycogen Synthase Kinase-3β and CDK5/P25, Two	
	'-	Proteins Kinases Involved in Abnormal Tau Phosphorylation in Alzheimer's	
		Disease", The Journal of Biological Chemistry, 276(1): 251-260, 2001.	
-	43	Hotamisligil et al. "IRS-1-Mediated Inhibition of Insulin Receptor Tyrosine Kinase	
	'`	Activity in TNT-α- and Obesity-Induced Insulin Resistance", Science, 271: 665-667,	
		1996.	
	44	Tanti et al. "Serine/Threonine Phosphorylation of Insulin Receptor Substrate 1	
	' '	Modulates Insulin Receptor Signaling", The Journal of Biological Chemistry, 269(8):	
		6051-6057, 1994.	
-	45	Fahraeus et al. "Inhibition of PRB Phosphorylation and Cell-Cycle Progression by A	
		20-Residue Peptide Derived From P16 CDKN2/INK4A", Current Biology, 6(1): 84-	
		91, 1996.	
	46	Mitchell et al. "Heat-Stable Inhibitor Protein Derived Peptide Substrate Analogs:	
	''	Phosphorylation by cAMP-Dependent and cGMP-Dependent Protein Kinases", Am.	
		Chemical Soc., 1994.	
	47	Maniatis "Signal Transduction: Catalysis by A Multiprotein IkB Kinase Complex",	
	''	Science, 278(5339): 818, 1997. Extract.	
	48	American Diabetes Association "Standards of Medical Care for Patients With	
		Diabetes Mellitus", Diabetes Care, 17(6): 616-623, 1994.	
	49	Hawiger "Non-Invasive Intracellular Delivery of Functional Peptides", Curr. Opin.	
		Chem. Biol., 3: 89-94, 1999.	
	50	Moreno et al. "Glycogen Synthase Kinase 3 Phosphorylation of Different Residues in	
		the Presence of Different Factors: Analysis on TAU Protein", Mol.Cell.Biochem.,	
		165(1):47-54, 1996. Tab.1.	
	51	Correll et al. "Inhibition of GSK3 Beta Mediates Cell Survival Society For	
		Neuroscience Abstracts" 25(2): 1519, 1999. Abstract No. 605.8.	
	52	Oelrichs et al. "Unique Toxic Peptides Isolated From Sawfly Larvae in Three	
		Continents", Toxicon, 37(3): 537-544, 1999. Fig.3.	
	53	Fiol et al. "Ordered Multisite Protein Phosphorylation. Analysis of Glycogen	
		Synthase. Kinase-3 Action Using Model Peptide Substrates", The Journal of	
		Biological Chemistry, 265(11): 6061-6065, 1990. Vol.2: Abstract.	
	54	Barber et al. "Insulin Rescues Retinal Neurons From Apoptosis by A	
		Phosphotidylinositol 3-Kinase/Akt-Mediated Mechanism That Reduces the	
		Activation of Caspase-3", The Journal of Biological Chemistry, 276(350): 32814-	
		32821, 2001.	
	55	Bijur et al. "Glycogen Synthase Kinese-3β Facilities Staurosporine- and Heat-	
		Induced Apotosis", The Journal of Biological Chemistry, 275(11): 7583-7590, 2000.	
	56	Burke et al. "Potent Inhibition of Insulin Receptor Dephosphorylation by A Hexamer	
		Peptide Containing the Phosphotyrosyl Mimetic F2Pmp", Biochemical and	
		Biophysical Research Communications, 204(1): 129-134, 1994.	
	57	Burke et al. "4'-O[2(2-Fluoromalonyl)]-L-Tyrosine: A Phosphotyrosyl Mimic for the	
		Preparation of Signal Transduction Inhabitory Peptides", J. Med. Chem., 39: 1021-	
		1027, 1996.	
	58	Burke et al. "Small Molecule Interactions With Protein-Tyrosine Phosphatase PTP1B	
	100	Dance of all Dinam Projectic Interactions with Florent-Tyrosine Phosphatase FIFID	
		and Their Use in Inhibitor Design" Riochemistry 35: 15090-15006-1006	
	59	and Their Use in Inhibitor Design", Biochemistry, 35: 15989-15996, 1996. Chen et al. "Why Is Phosphonodifluoromethyl Phenylalanine A More Potent	

SEP 1 4 2005 8		Phosphata 17, Biochemical and Biophysical Research Communions, 216(3): 976-984,	
S. CHAPENET	60	Cheng et al. "Insulin-Like' Effects of Lithium Ion on Isolated Rat Adipocytes L. Stimulation of Glycogenesis Beyond Glucose Transport", Molecular and Cellular	
	61	Biochemistry, 56: 177-182, 1983. Chu et al. "Sequential Phosphorylation by Mitogen-Activated Protein Kinase and Glycogen Synthase Kinase 3 Represses Transcriptional Activation by Heat Shock	· · · · ·
	62	Factor-1", The Journal of Biological Chemistry, 271(48): 30847-30857, 1996. Cross et al. "Inhibition of Glycogen Synthase Kinase-3 by Insulin Mediated by	
		Protein Kinase B", Nature, 378: 785-789, 1995.	
	63	Cross et al. "Selective Small-Molecule Inhibitors of Glycogen Synthase Kinase-3 Activity Protect Primary Neurons From Death", Journal of Neurochemistry, 77: 94-102, 2001.	
	64	Crowder et al. "Glycogen Synthase Kinase-3ß Activity Is Critical for Neuronal Death Caused by Inhibiting Physpatidylinositol 3-Kinase or Akt But Not for Death Caused by Nerve Growth Factor Withdrawal", The Journal of the Biological Chemistry, 275(44): 34266-34271, 2000.	
	65	Dajani et al. "Crystal Structure of Glycogen Synthase Kinase 3β: Structural Basis for Phosphate-Primed Substrate Specificity and Autoinhibition", Cell, 105: 721-732, 2001.	
	66	Devlin et al. "Textbook of Biochemistry With Clinical Correlation", Wiley-Liss, 4th Ed., XVII-XXV, 1997.	
	67	Dugas et al. "Bioorganic Chemistry of the Amino Acids: Chemical Synthesis of Proteins", Springer Verlag, NY, P. 54-92, 1981.	
	68	Eldar-Finkelman et al. "Expression and Characterization of Glycogen Synthase Kinase-3 Mutants and Their Effect on Glycogen Synthase Activity in Intact Cells", Proc. Natl. Acad. Sci. USA, 93(19): 10228-10233, 1996.	
	69	Eldar-Finkelman et al. "Phosphorylation of Insulin Receptor Substrate 1 by Glycogen Synthase Kinase 3 Impairs Insulin Action", Prc. Natl. Acad. Sci. USA, 94(18): 9660-9664, 1997.	
	70	Eldar-Finkelman et al. "Increased Glycogen Synthase Kinase-3 Activity in Diabetes- and Obesity-Prone C57BL/6J Mice", Diabetes, 48(8): 1662-1666, 1999.	
	71	Fiol et al. "Formation of Protein Kinase Regognition Sites by Covalent Modification of Substrate. Molecular Mechanism for the Synergistic Action of Casein Kinase II and Glycogen Synthase Kinase 3", J. Biol. Chem., 262(29): 14042-14048, 1987.	
	72	Fiol et al. "Phosphoserine as A Recognition Determinant for Glycogen Synthase Kinase-3: Phosphorylation of A Synthetic Peptide Based on the G-Component of Protein Phosphatase-1", Arch. Biochem. Biophys., 267(2): 797-802, 1988.	
	73	Fiol et al. "A Secondary Phosphorylation of CREB341 at Ser129 Is Required for the cAMP-Mediated Control of Gene Expression. A Role for Glycogen Synthase Kinase-3 in the Control of Gene Expression", J. Biol. Chem., 269(51): 32187-32193, 1994.	
	74	Fu et al. "Design and Synthesis of A Pyrodone-Based Phosphtyrosine Mimetic", Bioorg. Med. Chem. Lett., 8(19): 2813-2816, 1998.	
	75	Gao et al. "Inhibition of Grb2 SH2 Domain Binding by Non-Phosphate-Containing Ligands. 2.4-(2-Malonyl)Phenylalanine as A Potent Phosphotyrosyl Mimetic", J. Med. Chem., 43(5): 911-920, 2000.	
	76	Gething et al. "Cell-Surface Expression of Influenza Haemagglutinin From A Cloned DNA Copy of the RNA Gene", Nature, 293(5834): 620-625, 1981.	
	77	Groves et al. "Structural Basis for Inhibition of the Protein Tyrosine Phosphatase 1B by Phosphotyrosine Peptide Mimetics", Biochemistry, 37(51): 17773-17783, 1998.	
	78	Hallstrom et al. "Regulation of Transcription Factor Pdr1p Function by An Hsp70 Protein in Saccharomyces Cerevisiae", Mol. Cell Biol., 18(3): 1147-1155, 1998.	
	79	Hanger et al. "Glycogen Synthase Kinase-3 Induces Alzheimers Disease-Like Phosphorylation of Tau: Generation of Paired Helical Filament Epitopes and Neuronal Localisatoin of the Kinase", Neuroscience Letters, 147: 58-62, 1992.	
	80	Hawiger "Cellular Import of Functional Peptides to Block Intracellular Signaling", Curr. Opin. Immunol., 9(2): 189-194, 1997.	
	81	He et al. "Glycogen Synthase Kinase-3 and Dorsoventral Patterning in Xenopus Embryos", Nature, 374(6523): 617-622, 1995.	
	82	Higashimoto et al. "Human P53 Is Phosphorylated on Serines 6 and 9 in Response to	

1 4 7005 E		Proc. Natl and. Sci. USA, 93: 8455-8459, 1996.	
TRAPENIES	84	Kole et al. Otein-Tyrosine Phosphatase Inhibition by A Peptide Containing the Phosphotyrosyl Mimetic, L-O-Malonyltyrosine", Biochem. Biophys. Res. Commun., 209(3): 817-822, 1995.	
	85	Kole et al. "Specific Inhibition of Insulin Receptor Dephosphorylation by A Synthetic Dodecapeptide Containing Sulfotyrosyl Residues as Phosphotyrosyl Mimetic", Indian. J. Biochem. Biophys., 34(1-2): 50-55, 1997.	
	86	Latimer et al. "Stimulation of MAP Kinase by V-Raf Transformation of Fibroblasts Fails to Induce Hyperphosphorylation of Transfected Tau", FEBS Lett., 365: 42-46, 1995.	
	87	Lucas et al. "Decreased Nuclear Beta-Catenin, Tahyperphosphorylation and Neurodegeneration in GSK-3Beta Conditional Transgenic Mice", EMBO J., 20:27-39, 2001.	
_	88	Lovestone et al. "Alzheimer's Disease-Like Phosphorylation of the Microtubule-Associated Protein Tau by Glycogen Synthase Kinase-3 in Transfected Mammalian Cells", Current Biology, 4: 1077-1086, 1995.	
	89	Mandelkow et al. "Tau as A Marker for Alzheimer's Disease", Trends Biochem. Sci., 18(12): 480-483, 1983.	
	90	Mandelkow et al. "Glycogen Synthase Kinase-3 and the Alzheimer-Like State of Micortubule-Associated Protein Tau", FEBS Letters, 314: 315-321, 1992.	
	91	Manji et al. "Lithium at 50: Have the Neuroprotective Effects of This Unique Cation Been Overlooked?", Biol. Psychiatry, 46(7): 929-940, 1999.	
	92	McKinsey et al. "Phosphorylation of the PEST Domain of IkappaBbeta Regulates the Function of NF-KappaB/IkappaBbeta Complexes", J. Biol. Chem., 272(36): 22377-22380, 1997.	**
	93	Merrifield et al. "Solid Phase Peptide Synthesis. I. The Synthesis of A Tetrapeptide", J. Am. Chem. Soc., 85: 2149-2154, 1963.	
	94	Mikol et al. "The Crystal Structures of the SH2 Domain of P56Ick Complexed With Two Phosphonopeptides Suggest A Gated Peptide Binding Site", J. Mol. Biol., 246(2): 344-355, 1995.	
	95	Morrison et al. "Organic Chemistry", Allyn and Bacon, 5th Ed., V-XXIV,1987.	1.41
	96	Mulot et al. "PHF-Tau From Alzheimer's Brain Comprises Four Species on SDS-PAGE Which Can Be Mimicked by In Vitro Phosphorylation of Human Brain Tau by Glycogen Synthase Kinase-3 Beta", FEBS Lett., 349(3): 359-364, 1994.	
	97	Mulot et al. "Phosphorylation of Tau by Glycogen Synthase Kinase-3 Beta In Vitro Produces Species With Similar Electrophoretic and Immunogenic Properties to PHF-Tau From Alzheimer's Disease Brain", Biochem. Soc. Trans., 23(1): 45S, 1995.	
	98	Myers et al. "IRS-1 Activates Phosphatidylinositol 3'-Kinase by Associating With SRC Homology 2 Domains of P85D", Proc. Natl. Acad. Sci. USA, 89(21): 10350-10354, 1992.	
	99	Nicolaou et al. "Design and Synthesis of A Peptidomimeticemploying β-D-Glucose for Scaffolding", Peptides, ESCOM, 1990.	
	100	Nikoulina et al. "Regulation of Glycogen Synthase Activity in Cultured Skeletal Muscle Cells From Subjects With Type II Diabetes: Role of Chronic Hyperinsulinemia and Hyperglycemia", Diabetes, 46(6): 1017-1024, 1997.	
	101	Nikoulina et al. "Potential Role of Glycogen Synthase Kinase-3 in Skeletal Muscle Insulin Resitance of Type 2 Diabetes", Diabetes, 49(2): 263-271, 2000.	
	102	Nonaka et al. "Chronic Lithium Treatment Robustly Protects Neurons in the Central Nervous System Against Excitotoxicity by Inhibiting N-Methyl-D-Aspartate Rectpro-Mediated Calcium Influx", Proc. Natl. Acad. Sci. USA, 95: 2642-2647, 1998.	

L	
Signature	Considered

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1. Applicant's unique citation designation number (optional).

2. Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14, this collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS.

SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.